Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciprofloxacin inhalation - Bayer/Novartis

Drug Profile

Ciprofloxacin inhalation - Bayer/Novartis

Alternative Names: Bay q 3939; BAYQ3939; Cipro DPI; Cipro inhale; Ciprofloxacin PulmoSphere®; Ciprofloxin inhalation powder programme

Latest Information Update: 21 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare; Nektar Therapeutics
  • Developer Bayer HealthCare; Novartis
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Bronchiectasis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cystic fibrosis-associated respiratory tract infections; Pneumonia; Pseudomonal infections; Respiratory tract infections
  • Discontinued Bronchiectasis

Most Recent Events

  • 18 May 2018 Efficacy data from the phase III RESPIRE 1 and RESPIRE 2 trial in Bronchiectasis (non-cystic fibrosis bronchiectasis) presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 03 Apr 2018 No recent reports of development identified - Phase-III for Pneumonia in Japan (Inhalation)
  • 01 Oct 2016 Bayer and Novartis completes the phase III RESPIRE-2 trial in Bronchiectasis in USA, Argentina, Brazil, Australia, Austria, Bulgaria, Czech Republic, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, South Africa, South Korea, Hong Kong, China, Philippines, Taiwan, Thailand, Turkey, Serbia and Russia (NCT02106832)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top